Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 5, 2007, Pages 543-549

  Christoforidou, Anna V ^a   Saliba, Rima M ^a   Williams, Patricia ^a   Qazilbash, Muzaffar ^a   Roden, Linda ^a   Aleman, Ana ^a   Weber, Donna ^a   Mendoza, Floralyn ^a   Podoloff, Donald ^a   Wendt III, Richard ^a   Breitz, Hazel ^b   Alexanian, Raymond ^a   Champlin, Richard ^a   Giralt, Sergio ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Poniard Pharmaceuticals Inc   (United States)

Author keywords

Autologous stem cell transplant; High dose therapy; Myeloma; Targeted skeletal radiotherapy

Indexed keywords

HOLMIUM ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID) HO 166; MELPHALAN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; RADIATION DOSE; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; WHOLE BODY RADIATION;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOLMIUM; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ORGANOPHOSPHORUS COMPOUNDS; RADIOISOTOPES; RETROSPECTIVE STUDIES; SURVIVORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 34247177131     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.12.448     Document Type: Article

References (24)

1. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 78 (2003) 21-33
2. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 335 (1996) 91-97
3. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 348 (2003) 1875-1883
4. Reece D.E., Bredeson C., Perez W.S., et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone Marrow Transplant. 32 (2003) 1135-1143
5. Lenhoff S., Hjorth M., Holmberg E., et al., Nordic Myeloma Study Group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 95 (2000) 7-11
6. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99 (2002) 731-735
7. Deeg H.J., and Seattle Marrow Transplant Team. Acute and delayed toxicities of total body irradiation. Int J Radiat Oncol Biol Phys. 9 (1983) 1933-1939
8. Ackery D., and Yardley J. Radionuclide-targeted therapy for the management of metastatic bone pain. Semin Oncol. 20 (1993) 27-31
9. Collins C., Eary J.F., Donaldson G., et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 34 (1993) 1839-1844
10. Mertens W.C. Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy. Semin Oncol. 20 (1993) 49-55
11. Porter A.T., and Davis L.P. Systemic radionuclide therapy of bone metastases with strontium-89. Oncology (Williston Park) 8 (1994) 93-96
12. Bayouth J.E., Macey D.J., Kasi L.P., et al. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med. 36 (1995) 730-737
13. Appelbaum R., Sandmeier B., and Brown P. Myelosuppression and mechanism of recovery following administration of Samarium-EDTMP. Antibody Immunoconj Radiopharmaceut. (1988) 263-268
14. Spiers F.W., and Vaughan J. The toxicity of the bone seeking radionuclides. Leuk Res. 13 (1989) 347-350
15. Bayouth J.E., Macey D.J., Boyer A.L., et al. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation. Med Phys. 22 (1995) 743-753
16. Giralt S., Bensinger W., Goodman M., et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 102 (2003) 2684-2691
17. Goodman M., Bensinger W.I., Giralt S., et al. Holmium-166 (166Ho)-DOTMP skeletal targeted radiotherapy (STRTM) with melphalan and autologous peripheral stem cell transplant (PBSCT) for multiple myeloma (MM). ASH Ann Meet Abstr. 104 (2004) 922
18. Blade J., Samson D., Reece D., et al., Myeloma Subcommittee of the EBMT, European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 102 (1998) 1115-1123
19. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53 (1958) 457-481
20. Peto R., and Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc. 35 (1972) 185-207
21. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B 34 (1972) 187-220
22. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol. 23 (2005) 3412-3420
23. Durie B.G.M., and Salmon S.E. Recent Advances in Haematology (1977), Churchill Livingstone, Edinburgh, United Kingdom
24. Dispenzieri A., Wiseman G.A., Lacy M.Q., et al. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 19 (2005) 118-125